Key Highlights
- LucentAD Complete by Lucent Diagnostics enhances Alzheimer’s detection using a multi-marker approach.
- Reduces patients in the “intermediate zone” of uncertainty by threefold, cutting the need for invasive follow-up tests.
- Utilizes five AD biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP) for better classification accuracy.
- Backed by Alzheimer’s Drug Discovery Foundation funding and tested in over 1,000 patients across three independent cohorts.
Source: Business Wire
Notable Quotes
- “In over 1,000 patients across three independent clinical cohorts, we achieved guideline performance standard for a blood-based Alzheimer’s diagnostic test, while significantly increasing conclusive results for more patients versus p-Tau 217 alone.” — Masoud Toloue, CEO at Quanterix
- “Alzheimer’s is a multifaceted disease and as such, we will need a multi biomarker approach to detect the various underlying pathologies.” — Howard Fillit, MD, Chief Science Officer at Alzheimer’s Drug Discovery Foundation
SoHC's Take
Lucent Diagnostics’ introduction of LucentAD Complete marks a major step forward in Alzheimer’s diagnostics. By leveraging a multi-marker approach, this test overcomes the limitations of single-biomarker tests, particularly in patients whose results fall in the ambiguous “intermediate zone.” With its reduction of inconclusive cases by threefold, LucentAD Complete paves the way for more accurate and accessible Alzheimer’s diagnostics. The use of Quanterix’s Simoa® platform reinforces the potential of advanced biomarker detection in evolving toward a precision medicine model in Alzheimer’s care.
